Angiotensin II: Uses, Mechanism, and Side Effects

Key takeaways

• Angiotensin II is an FDA-approved vasoconstrictor used to raise blood pressure in adults with septic or other distributive shock.
• It works by binding to receptors on blood vessel walls, triggering smooth muscle contraction and aldosterone release.
• More than 890 registered trials reference angiotensin II, spanning cardiovascular and renal research.
• FAERS reports most often mention drug ineffectiveness, off-label use, and complications associated with critical illness such as acute kidney injury.
• The label does not carry a boxed warning.

What Angiotensin II Is

Angiotensin II is a peptide hormone given by injection to constrict blood vessels and raise blood pressure. It is classified as a vasoconstrictor. The mechanism works by binding to the angiotensin II receptor type 1, a G-protein coupled receptor on vascular smooth muscle cells. This binding stimulates calcium-dependent phosphorylation of myosin, causing the muscle to contract and the vessel to narrow. The hormone also increases aldosterone release, which contributes to its blood pressure effect. It is sold under the brand name Angiotensin II and identified by PubChem CID 172198.

What Angiotensin II Is Approved For

Angiotensin II Injection is approved to increase blood pressure in adults experiencing septic or other distributive shock, a condition in which blood vessels lose their normal tone. It functions as a vasoconstrictor in this setting, helping restore adequate circulation. The label does not carry a boxed warning.

What the Evidence Shows

Angiotensin II appears in nearly 900 registered clinical trials covering a range of cardiovascular and metabolic research questions. One recruiting Phase 3 trial is evaluating a related therapy in patients with focal segmental glomerulosclerosis who are also receiving an angiotensin receptor blocker. A completed trial examined genetic factors influencing responses to antihypertensive drugs, while a separate Phase 2 trial of unknown status studied intensive multifactorial therapy and endothelial function in newly diagnosed type 2 diabetes.

Reported Side Effects

FAERS data reflect reports submitted to a safety surveillance system, not confirmed incidence or causation. The most frequently reported issue is drug ineffectiveness (72 reports), followed by off-label use (31) and death (26). Several reports describe complications common in critically ill patients receiving vasoconstrictor therapy, including acute kidney injury (25), toxicity to various agents (19), distributive shock (17), peripheral ischaemia (17), and hypotension (16). Because angiotensin II is used in severely ill populations, these reports likely reflect the underlying condition as much as the drug itself.